Chemotherapy of stage IIIB and IV non-small-cell lung cancer

Cojean, I.; Chevalier, Thierry Le

doi:10.1093/annonc/6.suppl_3.s41

Cited by 17 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to improve further the activity for the new chemotherapeutic agents with significant activity in NSCLC, they most likely are to be combined with a platinum analogue, which has been the focus of several investigations (Sørensen, 1994;Cojean et al, 1995;Edelman et al, 1996). A review of vindesine in NSCLC covering accumulated data from eight randomized studies, including a total of 466 patients receiving vindesine + cisplatin, revealed 141 responding patients (30% response rate, 95% confidence limits 26-34%), with response rate in the individual studies ranging from 19% to 67% (Sørensen et al, 1993).…”

Section: Discussionmentioning

confidence: 99%

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

et al. 1999

View full text Add to dashboard Cite

Summary Because both vindesine and gemcitabine are active drugs in advanced non-small-cell lung cancer (NSCLC), with different modes of action and only partly overlapping toxicity, a phase II study was performed. Gemcitabine 1000 mg m -2 was given on days 1, 8 and 15 every 4 weeks, while vindesine 3 mg m -2 was administered weekly for 7 weeks, then every 2 weeks. A total of 42 patients with nonresectable NSCLC were included. The median age of patients was 56 years; 57% were men, 52% had adenocarcinoma, 31% squamous cell carcinoma and 17% had large-cell carcinoma. The performance status ranged from 0 to 2 with 83% in performance status 1. The majority (55%) had stage IV disease, while 40% had stage III B and 5% stage III A disease. WHO grade 3-4 leucopenia occurred in five patients (12%) and 9% had grade 4 neutropenia. Thrombocytopenia grade 3-4 was observed in six patients (15%). There were no septic death or bleeding episodes. One patient had a transient WHO grade 4 increase in bilirubin, and four patients had a decrease in glomerular filtration rate below the normal limit; one of these patients developed a non-reversible renal insufficiency. Ten patients (24%) complained of dyspnoea of uncertain mechanism, possibly involving bronchoconstriction. There were one complete and seven partial responses among 40 assessable patients (20%, 95% confidence limits 9-36%). Median response duration was 31 weeks (range 11-83 weeks) and median survival time 31 weeks (range 2-171 weeks). The current combination of gemcitabine and vindesine does not appear to be promising for further examination because of the toxicity and somewhat disappointing activity.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

et al. 1999

View full text Add to dashboard Cite

show abstract

“…(7) How often will I need blood tests? (8) What are the side effects? (9) What is the out-of-pocket cost of Treatment?…”

Section: Design Panelmentioning

confidence: 99%

“…As part of determining a treatment plan, clinicians are encouraged to engage patients in shared decision making (SDM) about recommended options [8][9][10][11]. Treatment SDM is a patient-centered process in which the clinical team provides patients and caregivers with information about the diagnosis, prognosis, and available treatment options; elicits patient values related to recommended treatment alternatives; clarifies personal preference related to the options, and helps the patient choose an option that is consistent with personal goals and optimal clinical care [12].…”

Section: Introductionmentioning

confidence: 99%

Engaging Patients with Late-Stage Non-Small Cell Lung Cancer in Shared Decision Making about Treatment

Myers

Advani

Myers

et al. 2021

JPM

View full text Add to dashboard Cite

Few treatment decision support interventions (DSIs) are available to engage patients diagnosed with late-stage non-small cell lung cancer (NSCLC) in treatment shared decision making (SDM). We designed a novel DSI that includes care plan cards and a companion patient preference clarification tool to assist in shared decision making. The cards answer common patient questions about treatment options (chemotherapy, chemotherapy plus immunotherapy, targeted therapy, immunotherapy, clinical trial participation, and supportive care). The form elicits patient treatment preference. We then conducted interviews with clinicians and patients to obtain feedback on the DSI. We also trained oncology nurse educators to implement the prototype. Finally, we pilot tested the DSI among five patients with NSCLC in treatment SDM at the beginning of an office visit scheduled to discuss Treatment with an oncologist. Analyses of pilot study baseline and exit survey data showed that DSI use was associated with increased patient awareness of the alternatives’ treatment options and benefits/risks. In contrast, patient concern about treatment costs and uncertainty in treatment decision making decreased. All patients expressed a treatment preference. Future randomized controlled trials are needed to assess DSI implementation feasibility and efficacy in clinical care.

show abstract

“…Lung cancer is the most common type of cancer worldwide and the leading cause of cancer‐related death 1 . Approximately 85% of individuals with lung cancer have non‐small‐cell lung cancer (NSCLC), with 70% of NSCLC tumors being inoperable, locally advanced, or metastatic at diagnosis 2 . Molecular targeting agents such as epidermal growth factor receptor ( EGFR )‐tyrosine kinase inhibitors (TKIs), anaplastic lymphoma kinase ( ALK )‐TKIs, c‐ros oncogene 1 ( ROS1 )‐TKIs, and v‐raf murine sarcoma viral oncogene homolog B1 ( BRAF )‐TKIs have markedly improved progression‐free survival (PFS) and overall survival (OS) in patients with NSCLC who are positive for the corresponding genetic alterations 3‐7 .…”

Section: Introductionmentioning

confidence: 99%

Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L

et al. 2021

View full text Add to dashboard Cite

Considering the increasing number of identified driver oncogene alterations, additional genetic tests are required to determine the treatment for advanced nonsmall-cell lung cancer (NSCLC). Next-generation sequencing can detect multiple driver oncogenes simultaneously, enabling the analysis of limited amounts of biopsied tissue samples. In this retrospective, multicenter study (UMIN ID000039523), we evaluated real-world clinical data using the Oncomine Dx Target Test Multi-CDx System (Oncomine DxTT) as a companion diagnostic system. Patients with NSCLC who were tested for a panel of 46 genes using the Oncomine DxTT between June 2019 and January 2020 were eligible for enrollment. Patients from 19 institutions affiliated to the West Japan Oncology Group were recruited. The primary endpoint

show abstract

Chemotherapy of stage IIIB and IV non-small-cell lung cancer

Cited by 17 publications

References 25 publications

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

Engaging Patients with Late-Stage Non-Small Cell Lung Cancer in Shared Decision Making about Treatment

Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L

Contact Info

Product

Resources

About